| Literature DB >> 23148583 |
Richard Baillot1, Éric Fréchette, Daniel Cloutier, Josep Rodès-Cabau, Daniel Doyle, Éric Charbonneau, Siamak Mohammadi, Éric Dumont.
Abstract
OBJECTIVE: The present study was undertaken to examine the incidence and management of surgical site infection (SSI) in patients submitted to transapical transcatheter aortic valve implantation (TA-TAVI).Entities:
Mesh:
Year: 2012 PMID: 23148583 PMCID: PMC3541989 DOI: 10.1186/1749-8090-7-122
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.637
Demographics of TA-TAVI hospital-acquired infections
| 1. AB | F | 79 | 65 | 66/33 | TIA | 23 | Pneumothorax |
| | | | | | Hypothyroidism | | UTI |
| | | | | | Previous CABG | | CK-MB: 32.4 |
| | | | | | Cr cl: 31.0 | | |
| 2. JGC | M | 79 | 50 | 78/27 | AF/COPD | 26 | AF, renal failure, |
| | | | | | PVD | | heart failure, pneumonia, empyema CK-MB: 33.4 |
| | | | | | Gout | | |
| | | | | | RA/steroids | | |
| | | | | | History DVT Previous CABG | | |
| | | | | | Cr cl: 31.8 | | |
| 3. IR | F | 76 | 65 | 72/30 | Hypothyroidism | 23 | AF/Flutter |
| | | | | | Previous DVT/PE | | CK-MB: 18.8 |
| | | | | | Porcelain aorta | | |
| | | | | | Cr cl: 61.8 | | |
| 4.MB | F | 64 | 50 | 92.5/35.2 | DM/MI | 26 | Heart failure |
| | | | | | Pulmonary emboli | | CK-MB: 12.4 |
| | | | | | Lung Ca/Rorx | | |
| | | | | | Cr cl: 69.4 | | |
| 5. CR | F | 77 | 20 | 82/31.2 | PAF/PVD | 26 | Heart failure |
| | | | | | Hypothyroidism | | CK-MB : 12.4 |
| | | | | | Active smoker | | |
| | | | | | COPD | | |
| | | | | | Heart failure | | |
| Cr cl: 26.5 |
AF Atrial fibrillation, CA cancer; CABG; Coronary artery bypass grafting; Cr cl, Creatinine (clearance ml/min); COPD Chronic obstructive pulmonary disease; DVT Deep venous thrombosis; DM Diabetes mellitus; MI Myocardial infarction; PAF, Paroxysmal AF; PE Pulmonary emboli; RA Rheumatoid arthritis; RoRX radiotherapy.
Figure 1Chronic sinus leading to left ventricular apex.
TA-TAVI infection vs no-infection demographic and operative variables
| | |||
|---|---|---|---|
| Age | 78.7±7.9 | 75±6.3 | 0.3079 |
| Men (%) | 43.0 (64/149) | 20 (1/5) | 0.3067 |
| Weight (kg) | 67.1±14.9 | 78.2±10 | 0.0996 |
| BMI | 26.7±5.3 | 31.4±3.1 | 0.0504 |
| HBP (%) | 82.6 (123/149) | 100 (5/5) | 0.3056 |
| DM (%) | 34.2 (51/149) | 20 (1/5) | 0.5081 |
| Cr.clearance (median) | 39.7±16.5 (37.5) | 44.1±19.9 (31.8) | 0.5580 |
| DLP (%) | 89.9 (134/149) | 100 (5/5) | 0.4552 |
| PVD (%) | 45.6 (68/149) | 40 (2/5) | 0.8033 |
| COPD (%) | 26.2 (39/149) | 40 (2/5) | 0.4915 |
| Stroke (%) | 3.4 (5/149) | 0 (0/5) | 0.6771 |
| GI comp (%) | 6.7 (10/149) | 20 (1/5) | 0.2564 |
| ARF (%) | 18.1 (27/149) | 20 (1/5) | 0.9147 |
| Septicaemia (%) | 0 | 0 | - |
| Bronchitis/Pneumonia (%) | 21.5 (32/149) | 40 (2/5) | 0.3260 |
| UTI (%) | 18.1 (27/149) | 20 (1/5) | 0.9147 |
| Death (%) | 12.8 (19/149) | 0 | 0.3938 |